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ABSTRACT
This report presents updated time-to-event variables from a multicenter phase II trial of reduced-dose 90Y
ibritumomab tiuxetan in patients with relapsed or refractory low-grade, follicular, or transformed B-cell
non-HodgkinÕs lymphoma (NHL) and mild thrombocytopenia (platelet counts of 100 to 149 3 109
platelets/L). Patients received a single course of ibritumomab tiuxetan radioimmunotherapy, with 90Y ib-
ritumomab tiuxetan administered at 0.3 mCi/kg (compared to a standard dose of 0.4 mCi/kg). In 30 pa-
tients, the overall response rate was 83%, with complete responses (confirmed [CR] and unconfirmed
[CRu]) of 47%. Median follow-up time is currently 36.5 months (range: 7.5—54.9 months). Median du-
ration of response was 11.5 months (range: 1.0—53.9 months), median time to progression was 9.4 months
(range: 1.7—54.81 months), and median time to next lymphoma therapy was 14.6 months (range:
2.3—54.91 months). Median overall survival time has not yet been reached. Long-term responses, defined
as time to progression of 12 months or greater, have been seen in 14 of 30 patients (47%) overall, and
12 of 14 CR/CRu patients (86%). Toxicities were primarily hematologic and reversible. No additional
long-term adverse events have been observed in the follow-up period, and treatment did not preclude sub-
sequent lymphoma therapies.
Key words: ibritumomab tiuxetan, radioimmunotherapy, non-HodgkinÕs lymphoma, therapy, thrombo-
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The clinical course of low-grade or follicular B-
cell non-HodgkinÕs lymphomas (NHL) is char-
acterized by initial responsiveness to therapy and
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a continuous pattern of multiple remissions and
relapses. Patients usually receive several differ-
ent lymphoma therapies over the course of their
disease. Persistent mild thrombocytopenia is seen
in a number of patients with relapsed or refrac-
tory NHL, and may be indicative of compromised
bone marrow reserve from prior therapy, lym-
phomatous bone marrow involvement, or both.
Patients with baseline thrombocytopenia are at
increased risk for chemotherapy-induced myelo-
suppression and its associated complications.1 As
such, the treatment of patients with low-grade or
follicular B-cell NHL and persistent mild throm-
bocytopenia presents a clinical challenge.
Radioimmunotherapy with ibritumomab tiuxe-
tan is an effective treatment option for patients
with relapsed or refractory low-grade, follicular,
or transformed B-cell NHL.2—4 It was recognized
early in the clinical development of ibritumomab
tiuxetan that baseline platelet count, an indicator
of bone-marrow reserve, correlated with the risk
of hematologic toxicity. Early in the phase I/II
study, investigators noted that patients with base-
line mild thrombocytopenia treated with 90Y ibri-
tumomab tiuxetan at a dose of 0.4 mCi/kg were at
an increased risk of grade 4 hematologic toxicity,
compared to patients with normal baseline platelet
counts.2 Thereafter, patients with mild thrombo-
cytopenia, defined as a baseline platelet count of
100 to 149 3 109 platelets/L, received a reduced
dose of 90Y-ibritumomab tiuxetan of 0.3 mCi/kg.
Subsequently, a phase II trial was conducted to
evaluate the safety and efficacy of reduced-dose
90Y ibritumomab tiuxetan radioimmunotherapy
in 30 patients with relapsed or refractory low-
grade, follicular, or transformed B-cell NHL and
mild thrombocytopenia (platelet counts of 100 to
149 3 109 platelets/L). Results from this study
were first reported in 2002.5 Patients received a
single course of treatment, in which 90Y ibritu-
momab tiuxetan was administered at a dose of
0.3 mCi/kg. The overall response rate was 83%
using International Workshop response criteria.6
Toxicities were primarily hematologic, and were
transient and reversible. This report provides up-
dated data on response and survival outcomes
from an additional 2 years of follow-up time.
METHODS
A detailed description of the design and methods
of this single-arm, multicenter phase II study has
been previously reported.5 Briefly, patients age
18 or above with histologically confirmed relapsed
or refractory low-grade, follicular, or transformed
CD201 NHL and mild thrombocytopenia, defined
as a baseline platelet count 100 to 149 3 109
platelets/L were eligible for enrollment. Patients
had to have bidimensionally measurable disease,
with at least 1 lesion measuring 2.0 cm or greater
in a single dimension. Additional eligibility crite-
ria included less than 25% bone marrow involve-
ment; baseline World Health Organization (WHO)
performance status of 0, 1, or 2; no prior mye-
loablative therapy; and no prior radioimmunother-
apy or anti-CD20 therapy. Patients had to have oth-
erwise adequate hematologic and hepatic function
and provide written, informed consent.
On day 1 of therapy, patients received an i.v.
infusion of rituximab 250 mg/m2 followed by an
imaging dose of 111In ibritumomab tiuxetan 5
mCi (185 MBq). Provided biodistribution was
adequate on gamma-camera images, approxi-
mately 1 week later patients received a second in-
fusion of rituximab 250 mg/m2, followed by 90Y
ibritumomab tiuxetan 0.3 mCi/kg (11 MBq/kg),
up to a maximum dose of 32 mCi (1.2 GBq).
Statistical Design
The primary study endpoint was overall response
rate (ORR), with complete response (CR/CRu)
rate, partial response (PR) rate, time to progres-
sion (TTP), duration of response (DR), and time
to next NHL therapy (TTNT) evaluated as sec-
ondary endpoints. Response rates were deter-
mined using International Workshop NHL re-
sponse criteria.6
Definitions for time-to-event variables were as
follows: TTP was the time interval between the
date of the first treatment infusion to the date of
progression or date of last known contact for cen-
sored patients; DR was the time interval between
the date of the first IWRC response and the date
of disease progression; TTNT was the time in-
terval between the date of the first treatment in-
fusion to the date of the first subsequent NHL
therapy; overall survival (OS) was the time in-
terval between the date of the first treatment in-
fusion to date of death or last cutoff date for cen-
sored patients. Median TTP, DR, TTNT, and OS
were estimated using the Kaplan-Meier method.7
RESULTS
The study enrolled a total of 30 patients between
May 1998 and August 1999, with a current fol-
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low-up through August 2003, for a median fol-
low-up time of 36.5 months (range: 7.5—54.81
months). All 30 patients enrolled were evaluable
for response and toxicity. Baseline patient char-
acteristics are listed in Table 1. Patients had re-
ceived a median of 2 prior therapies for NHL
(range: 1—9). Nineteen (19) patients (63%) were
resistant to at least 1 prior chemotherapy, and 14
patients (47%) were resistant to their last che-
motherapy. Resistance was defined as a failure to
achieve a complete or partial response, or disease
progression, within 6 months.
Overall, 25 of 30 patients (83%) responded to
therapy, with 11 CR (37%), 3 CRu (10%) and 11
PR (37%) by International Workshop response
criteria.6 The median duration of response was
11.5 months (range: 1.0—53.9 months). The me-
dian time to progression for all patients was 9.4
months (range: 1.7—54.81 months) (Fig. 1).
Overall, responses have been durable. Long-term
responses, defined as time to progression of 12
months or greater, has been seen in 14 of 30 pa-
tients (47%) overall, including 12 of 14 patients
(86%) who achieved a CR or CRu (the 2 patients
who relapsed within 12 months were true CRs,
not CRus). Median TTP in the 14 patients achiev-
ing long-term responses of 12 months or greater
was 24.6 months (range: 12.1—54.81 months),
and median TTP in all CR/CRu patients (inde-
pendent of CR/Cru duration) was 24.5 months
(range: 4.9—54.8 months). Two (2) patients had
long-term partial responses of 12.6 and 17.3
months, respectively. These 2 patients had a re-
sidual mass on computed tomography (CT) scan
that did not meet CRu criteria but was more likely
fibrosis/scar than viable tumor, accounting for the
long duration of response. Functional imaging
with positron emission tomography (PET) was
not done, but may have better defined these re-
sidual masses. Two (2) of the patients have re-
mained in continuous, complete remission for 41
and 54.81 months, respectively, following ibri-
tumomab tiuxetan radioimmunotherapy.
Median overall survival time has not yet been
reached (data not shown). Overall median TTNT
was 14.6 months (range: 2.3—54.81 months). A
total of 24 patients received treatment subsequent
to ibritumomab tiuxetan radioimmunotherapy,
including rituximab, chemotherapy, and other
therapies. In the 13 patients who received ritux-
imab as their first NHL treatment following ibri-
tumomab tiuxetan radioimmunotherapy, clinical
responses were observed in 6 patients, 3 patients
did not respond to therapy, and clinical outcome
was unknown in the remaining 4 patients.
At this time, 7 of 30 patients enrolled in this
study have died; 6 deaths were the result of dis-
ease progression, and 1 death was the result of
other causes. In the original report, 1 patient with
a history of chronic alkylator exposure developed
acute myelogenous leukemia 20 months after
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Median age (yrs.), range 61 (29—85)
Histology






Degree of bone marrow involvement
0 to ,5% 10 33
5% to 20% 12 40
20% to ,25% 8 27
No. of extranodal disease sites
0 or 1 24 80
2 or more 6 20
Tumor size
,5 cm 16 53
5 to ,7 cm 9 30
7 to ,10 cm 3 10
10 cm or more 2 7
Splenomegaly 7 23
Median no. of prior chemotherapy 2 (1—9)
(range)
0

















































Figure 1. Time to progression (n 5 30); median time to
progression 5 9.4 months.
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study entry. With longer follow-up, there have
been no additional cases of secondary malignan-
cies or other long-term toxicities in this patient
cohort.
DISCUSSION
In this phase II trial, 30 patients with relapsed or
refractory low-grade, follicular, or transformed
B-cell NHL and mild thrombocytopenia received
a single course of radioimmunotherapy, with 90Y
ibritumomab tiuxetan administered at a reduced
dose of 0.3 mCi/kg. Overall, 83% of patients re-
sponded to therapy, with 14 patients (47%)
achieving a CR or CRu. Responses have been
durable, with 14 of 30 patients overall, and 12 of
14 CR/CRu patients, having a time to disease pro-
gression in excess of 12 months. Median TTP for
all patients was 9.4 months, with a median TTNT
of 14.6 months. In the 14 patients with long-term
responses, median TTP was 24.6 months. At this
time, median overall survival time has not yet
been reached.
With respect to safety, toxicities were primar-
ily hematologic, but were transient and re-
versible.5 With extended follow-up, no long-term
adverse effects were noted, consistent with data
previously indicating that treatment with ibritu-
momab tiuxetan radioimmunotherapy is not as-
sociated with an increased risk of secondary ma-
lignancies.8 Recent reports have indicated that
subsequent NHL therapies, such as chemother-
apy, immunotherapy, and even high-dose therapy
with stem-cell or bone-marrow transplant, can be
safely administered to patients who have previ-
ously received 90Y ibritumomab tiuxetan ra-
dioimmunotherapy.9,10 In this study, 24 of 30 pa-
tients received one or more subsequent NHL
therapies.
CONCLUSION
Persistent mild thrombocytopenia in patients with
relapsed or refractory NHL is indicative of im-
paired bone-marrow reserves, either from prior
chemotherapy, lymphomatous bone marrow in-
volvement, or both. For these patients, treatment
with reduced-dose 90Y ibritumomab tiuxetan is
an effective option, producing a high rate of re-
sponse and durable remissions. Therapy is gen-
erally well tolerated, and does not preclude the
use of other subsequent lymphoma therapies.
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